Cellectar Biosciences Inc
Company Overview
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core technology is its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform, which is designed to specifically target cancer cells and deliver payloads for improved efficacy.
The company's lead product candidate is iopofosine I-131, a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. This compound is in clinical trials for various hematologic and solid tumor malignancies.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Cellectar Biosciences Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.